Fulcrum Asset Management LLP Purchases New Stake in Twist Bioscience Corporation $TWST

Fulcrum Asset Management LLP purchased a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 46,568 shares of the company’s stock, valued at approximately $8,668,000. Fulcrum Asset Management LLP owned approximately 0.07% of Twist Bioscience at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of TWST. Brighton Jones LLC purchased a new position in Twist Bioscience in the 3rd quarter valued at approximately $231,000. Ethic Inc. raised its holdings in Twist Bioscience by 77.9% during the 3rd quarter. Ethic Inc. now owns 5,425 shares of the company’s stock valued at $1,048,000 after acquiring an additional 2,376 shares during the period. StoneX Group Inc. purchased a new stake in shares of Twist Bioscience during the third quarter worth $361,000. Abacus Wealth Partners LLC lifted its position in shares of Twist Bioscience by 4.3% during the third quarter. Abacus Wealth Partners LLC now owns 2,332 shares of the company’s stock worth $451,000 after acquiring an additional 96 shares in the last quarter. Finally, CenterBook Partners LP purchased a new stake in shares of Twist Bioscience during the third quarter worth $388,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on TWST shares. Canaccord Genuity Group lifted their price target on Twist Bioscience from $120.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, October 12th. Leerink Partners increased their price objective on Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, September 21st. Guggenheim raised their target price on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Finally, Barclays lifted their target price on Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Twist Bioscience presently has a consensus rating of “Hold” and a consensus price target of $153.00.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $120.79 on Monday. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The business has a 50-day moving average price of $151.35 and a two-hundred day moving average price of $91.08. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $219.71. The firm has a market cap of $7.57 billion, a P/E ratio of -54.41 and a beta of 2.25.

Insider Transactions at Twist Bioscience

In related news, CFO Adam Laponis sold 8,057 shares of the firm’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,521,806.16. Following the transaction, the chief financial officer directly owned 100,576 shares of the company’s stock, valued at approximately $18,996,794.88. This trade represents a 7.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,905,421.44. Following the completion of the sale, the senior vice president owned 106,632 shares of the company’s stock, valued at $20,140,652.16. The trade was a 8.64% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 495,279 shares of company stock valued at $80,489,387. 3.08% of the stock is currently owned by corporate insiders.

Key Stories Impacting Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist launched MRD Express, potentially expanding its presence in minimal residual disease testing. Investors may look for further details on the product and business outlook around earnings. Article: Twist Bioscience stock enters earnings week after MRD Express launch
• Neutral Sentiment: CEO Emily Leproust and three other insiders sold a combined 6,677 shares at $135.40. The sales were disclosed as covering tax withholding on equity-award vesting, and each seller retained a substantial stake.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The provided article headline does not specify the report’s allegations, but its release appears to have hurt sentiment. Article: Twist Bioscience falls amid negative report

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications.

The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

Founded in 2013 and headquartered in South San Francisco, California, Twist serves customers in biotechnology, pharmaceutical, academic, agricultural and other industries around the world.